Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial reveals therapy response patterns in high-risk early-stage breast cancer, highlighting the clinical role of germline genetic variants.
Key Points
- To assess the relationship between germline genetic variant status and clinical response to therapy in patients with high-risk early-stage breast cancer.
- Interventional clinical trial registered under ClinicalTrials.gov Identifier NCT02125344.
- Evaluated therapeutic outcomes across germline variant profiles in patients diagnosed with high-risk early-stage breast cancer.
- Therapeutic responses were analyzed in relation to individual germline genetic variant classifications.
- Quantitative outcome measures including effect sizes, odds ratios, hazard ratios, confidence intervals, and p-values were not reported in the available summary.
Cite This Study
Pohl‐Rescigno et al. (2020) studied this question.